Compare HURN & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HURN | ZLAB |
|---|---|---|
| Founded | 2002 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2004 | 2017 |
| Metric | HURN | ZLAB |
|---|---|---|
| Price | $159.38 | $25.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $190.75 | $33.14 |
| AVG Volume (30 Days) | 196.1K | ★ 708.4K |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.46 |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $1,699,143,000.00 | $460,156,000.00 |
| Revenue This Year | $12.58 | N/A |
| Revenue Next Year | $8.97 | $26.50 |
| P/E Ratio | $119.23 | ★ N/A |
| Revenue Growth | 11.65 | ★ 15.33 |
| 52 Week Low | $84.88 | $15.96 |
| 52 Week High | $186.78 | $33.97 |
| Indicator | HURN | ZLAB |
|---|---|---|
| Relative Strength Index (RSI) | 54.14 | 51.50 |
| Support Level | $143.69 | $24.81 |
| Resistance Level | $165.37 | $27.20 |
| Average True Range (ATR) | 4.85 | 0.87 |
| MACD | 0.06 | -0.10 |
| Stochastic Oscillator | 47.11 | 41.28 |
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.